At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed breast carcinoma
- ✓Early stage breast cancer (stage 1, 2, or 3)
- ✓No distant metastases except ipsilateral axillary lymph nodes
- ✓Age 18 years or older
- ✕Prior chemotherapy, hormonal therapy, biologic therapy, or radiation therapy for breast cancer
- ✕Major surgery within 28 days of study entry
- ✕CNS metastases
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Capecitabine for Breast Cancer. Completed, enrolled 51 participants across 19 sites.
Detailed Summary
The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
Study Details
Timeline
Interventions
Sequential Therapy: Docetaxel will be given at 100 mg/m\^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles. Concurrent Therapy: Docetaxel will be given at 50 mg/m\^2 IV Day 1.
Sequential Therapy: administration of capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m\^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).